Long-term Efficacy and Safety of Low-dose Interferon Alpha2a Therapy in Severe Uveitis Associated With Behçet Disease

American Journal of Ophthalmology

Volumn 146, Issue 6, 2008, Pages

  Gueudry, Julie ^a   Wechsler, Bertrand ^a   Terrada, Céline ^a   Gendron, Gaël ^a   Cassoux, Nathalie ^a   Fardeau, Christine ^a   Lehoang, Phuc ^a   Piette, Jean Charles ^a   Bodaghi, Bahram ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVER ENZYME; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; BEHCET DISEASE; BLOOD CELL COUNT; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE EXAMINATION; EYE INFLAMMATION; FEMALE; FEVER; FLU LIKE SYNDROME; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THYROIDITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VASCULITIS; VISUAL ACUITY;

EID: 56249121565     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.08.038     Document Type: Article

References (54)

1. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 50 (2005) 297-350
2. Cassoux N., Fardeau C., and Lehoang P. Ocular manifestations of Behçet's disease. Ann Med Interne (Paris) 150 (1999) 529-534
3. Yurdakul S., Mat C., Tuzun Y., et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 44 (2001) 2686-2692
4. Yazici H., Pazarli H., Barnes C.G., et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322 (1990) 281-285
5. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., and Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1 (1989) 1093-1096
6. Bhisitkul R.B., and Foster C.S. Diagnosis and ophthalmological features of Behçet's disease. Int Ophthalmol Clin 36 (1996) 127-134
7. Ando K., Fujino Y., Hijikata K., Izawa Y., and Masuda K. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol 43 (1999) 312-317
8. Yoshida A., Kawashima H., Motoyama Y., et al. Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 111 (2004) 810-815
9. Tugal-Tutkun I., Onal S., Altan-Yaycioglu R., Huseyin Altunbas H., and Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138 (2004) 373-380
10. Cochereau-Massin I., Wechsler B., Le Hoang P., et al. Ocular prognosis in Behçet's disease. J Fr Ophtalmol 15 (1992) 343-347
11. El Belhadji M., Hamdani M., Laouissi N., Zaghloul K., Amraoui A., and Benamour S. Ophthalmological involvement in Behçet disease. Apropos of 520 cases. J Fr Ophtalmol 20 (1997) 592-598
12. Joseph A., Raj D., Dua H.S., Powell P.T., Lanyon P.C., and Powell R.J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110 (2003) 1449-1453
13. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., and van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89 (2005) 533-536
14. Murphy C.C., Ayliffe W.H., Booth A., Makanjuola D., Andrews P.A., and Jayne D. Tumor necrosis factor? blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111 (2004) 352-356
15. Ohno S., Nakamura S., Hori S., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31 (2004) 1362-1368
16. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., and Markomichelakis N.N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358 (2001) 295-296
17. Suhler E.B., Smith J.R., Wertheim M.S., et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123 (2005) 903-912
18. Wechsler B., Sable-Fourtassou R., Bodaghi B., et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 22 (2004) S14-S16
19. Brown S.L., Greene M.H., Gershon S.K., Edwards E.T., and Braun M.M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46 (2002) 3151-3158
20. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
21. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
22. Moore T.D., Horton R., Utrup L.J., Miller L.A., and Poupard J.A. Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay. J Clin Microbiol 34 (1996) 1321-1322
23. Feron E.J., Rothova A., van Hagen P.M., Baarsma G.S., and Suttorp-Schulten M.S. Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 343 (1994) 1428
24. Kotter I., Eckstein A.K., Stubiger N., and Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon-alpha 2a: a pilot study. Br J Ophthalmol 82 (1998) 488-494
25. Pivetti-Pezzi P., Accorinti M., Pirraglia M.P., Priori R., and Valesini G. Interferon-alpha for ocular Behçet's disease. Acta Ophthalmol Scand 75 (1997) 720-722
26. Bodaghi B., Gendron G., Wechsler B., et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91 (2007) 335-339
27. Guillaume-Czitrom S., Berger C., Pajot C., Bodaghi B., Wechsler B., and Kone-Paut I. Efficacy and safety of interferon-{alpha} in the treatment of corticodependent uveitis of paediatric Behçet's disease. Rheumatology (Oxford) 46 (2007) 1570-1573
28. Kotter I., Gunaydin I., Zierhut M., and Stubiger N. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum 33 (2004) 320-335
29. Tugal-Tutkun I., Guney-Tefekli E., and Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1692-1695
30. Wechsler B., Bodaghi B., Huong D.L., et al. Efficacy of interferon-alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 8 (2000) 293-301
31. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 335 (1990) 1078-1080
32. Bloch-Michel E., and Nussenblatt R.B. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103 (1987) 234-235
33. Jabs D.A., Nussenblatt R.B., and Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516
34. Alpsoy E., Durusoy C., Yilmaz E., et al. Interferon-alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138 (2002) 467-471
35. Kotter I., Gunaydin I., Treusch M., Zierhut M., Kanz L., and Stubiger N. The use of interferon-alpha in Behçet's disease-review of the literature and possible mechanisms of action. Adv Exp Med Biol 528 (2003) 503-509
36. Krause L., Turnbull J.R., Torun N., Pleyer U., Zouboulis C.C., and Foerster M.H. Interferon-alfa-2a in the treatment of ocular Adamantiades-Behçet's disease. Adv Exp Med Biol 528 (2003) 511-519
37. Zouboulis C.C., and Orfanos C.E. Treatment of Adamantiades-Behçet disease with systemic interferon-alfa. Arch Dermatol 134 (1998) 1010-1016
38. O'Duffy J.D., Calamia K., Cohen S., et al. Interferon-alpha treatment of Behçet's disease. J Rheumatol 25 (1998) 1938-1944
39. Sanchez Roman J., Pulido Aguilera M.C., Castillo Palma M.J., et al. The use of interferon- alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease). Rev Clin Esp 196 (1996) 293-298
40. Deuter C.M., Koetter I., Guenaydin I., Stuebiger N., and Zierhut M. Interferon-alfa-2a: a new treatment option for long-lasting refractory cystoid macular edema in uveitis?. A pilot study. Retina 26 (2006) 786-791
41. Plskova J., Greiner K., and Forrester J.V. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144 (2007) 55-61
42. Kotter I., Deuter C., Stubiger N., and Zierhut M. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN. J Rheumatol 32 (2005) 1633 author reply, 1634
43. Kotter I., Zierhut M., Eckstein A.K., et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87 (2003) 423-431
44. BenEzra D., Cohen E., Chajek T., et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 20 (1988) 136-143
45. Nussenblatt R.B., Palestine A.G., Chan C.C., Mochizuki M., and Yancey K. Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum 28 (1985) 671-679
46. Ozyazgan Y., Yurdakul S., Yazici H., et al. Low-dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 76 (1992) 241-243
47. Sullu Y., Oge I., Erkan D., Ariturk N., and Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand 76 (1998) 96-99
48. Hamuryudan V., Ozyazgan Y., Fresko Y., Mat C., Yurdakul S., and Yazici H. Interferon-alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J 4 (2002) 928-930
49. Quesada J.R., Talpaz M., Rios A., Kurzrock R., and Gutterman J.U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 4 (1986) 234-243
50. Schulman J.A., Liang C., Kooragayala L.M., and King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 110 (2003) 437-442
51. Perlemuter G., Bodaghi B., Le Hoang P., et al. Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol 37 (2002) 701-702
52. Lohmann C.P., Kroher G., Bogenrieder T., Spiegel D., and Preuner J. Severe loss of vision during adjuvant interferon-alfa-2b treatment for malignant melanoma. Lancet 353 (1999) 1326
53. Mushtaq B., Saeed T., Situnayake R.D., and Murray P.I. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 21 (2007) 824-825
54. Sfikakis P.P., Markomichelakis N., Alpsoy E., et al. Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology (Oxford) 46 (2007) 736-741